Literature DB >> 9538174

Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma.

T Kurizaki1, M Toi, T Tominaga.   

Abstract

Intratumoral proteases are known to be involved in not only tumor cell invasion but also a variety of stromal reactions including neovascularization. In this study, we have examined the expression of matrix metalloproteinases (MMPs) by gelatin gel zymography and compared its expression with angiogenesis activities including the expression of several endothelial growth regulators and intratumoral microvessel density (MVD) in human breast cancer tissues. There was a significant correlation between activated MMP-2 expression and vascular endothelial growth factor (VEGF) expression (p=0.045). In addition, the expression of activated MMP-9 expression was significantly correlated with thymidine phosphorylase (TP) expression (p=0.0044). Pro MMP-9 expression tended to correlated with the increment of MVD (p=0.063). MMP-2 and MMP-9 expressions were frequently co-upregulated with endothelial growth regulators in human breast cancer tissues, which underlines the cooperative function of MMPs in neovascularization.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9538174     DOI: 10.3892/or.5.3.673

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  16 in total

1.  Expression of WTH3 in breast cancer tissue and the effects on the biological behavior of breast cancer cells.

Authors:  Lin Gan; Guoqing Zuo; Ting Wang; Jie Min; Yadong Wang; Yongyue Wang; Gang Lv
Journal:  Exp Ther Med       Date:  2015-04-29       Impact factor: 2.447

2.  Vascular endothelial growth factor165-regulated nasopharyngeal carcinoma cell lines invasion and migration involve expression and activation of matrix metalloproteinase-2.

Authors:  Yanjun Wang; Weijia Kong; Jianxin Yue; Dawei Sun; Wei Li; Qi Yao; Yu Sun; Jihua Dong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

3.  Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy.

Authors:  J Salzmann; G A Limb; P T Khaw; Z J Gregor; L Webster; A H Chignell; D G Charteris
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

Review 4.  Toward checkmate: biology and breast cancer therapy for the new millennium.

Authors:  K D Miller; G W Sledge
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  Suppression of matrix metalloproteinase activity by SI-27: detection by a new activity assay with S-2444, a specific chromogenic peptide.

Authors:  Daizo Yoshida; Kunihiro Watanabe; Masahiro Noha; Hiroshi Takahashi; Akira Teramoto
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

6.  High dietary inorganic phosphate enhances cap-dependent protein translation, cell-cycle progression, and angiogenesis in the livers of young mice.

Authors:  Cheng-Xiong Xu; Hua Jin; Hwang-Tae Lim; Ji-Eun Kim; Ji-Young Shin; Eun-Sun Lee; Youn-Sun Chung; Yeon-Sook Lee; George Beck; Kee Ho Lee; Myung-Haing Cho
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-08-14       Impact factor: 4.052

Review 7.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

Review 8.  Enzymatic aspects in ENT cancer-Matrix metalloproteinases.

Authors:  A A Zamfir Chiru; C R Popescu; D C Gheorghe
Journal:  J Med Life       Date:  2014-09-25

9.  Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers.

Authors:  A M Bajo; A V Schally; K Groot; K Szepeshazi
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

10.  Therapeutic effects of tyroservatide on metastasis of lung cancer and its mechanism affecting integrin-focal adhesion kinase signal transduction.

Authors:  Yu-ting Huang; Lan Zhao; Zheng Fu; Meng Zhao; Xiao-meng Song; Jing Jia; Song Wang; Jin-ping Li; Zhi-feng Zhu; Gang Lin; Rong Lu; Zhi Yao
Journal:  Drug Des Devel Ther       Date:  2016-03-03       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.